Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used
in combination with rituximab for patients with relapsing or refractory, low-grade or
follicular, CD-20-positive, B-Cell non-Hodgkin's Lymphoma. Safety will be the primary
objective of phase I, while the primary objective of phase II will be to determine overall
response.